BG105715A - Combination chemotherapy - Google Patents
Combination chemotherapyInfo
- Publication number
- BG105715A BG105715A BG105715A BG10571501A BG105715A BG 105715 A BG105715 A BG 105715A BG 105715 A BG105715 A BG 105715A BG 10571501 A BG10571501 A BG 10571501A BG 105715 A BG105715 A BG 105715A
- Authority
- BG
- Bulgaria
- Prior art keywords
- combination chemotherapy
- combination
- paclitaxel
- meanings
- substituents
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11329198P | 1998-12-22 | 1998-12-22 | |
US16478899P | 1999-11-10 | 1999-11-10 | |
PCT/US1999/030485 WO2000037141A1 (en) | 1998-12-22 | 1999-12-21 | Combination chemotherapy |
Publications (1)
Publication Number | Publication Date |
---|---|
BG105715A true BG105715A (en) | 2002-04-30 |
Family
ID=26810891
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BG105715A BG105715A (en) | 1998-12-22 | 2001-07-18 | Combination chemotherapy |
Country Status (31)
Country | Link |
---|---|
EP (1) | EP1140291B1 (xx) |
JP (1) | JP2002532570A (xx) |
KR (1) | KR20010099877A (xx) |
CN (1) | CN1333698A (xx) |
AP (1) | AP2001002175A0 (xx) |
AT (1) | ATE310567T1 (xx) |
AU (1) | AU2203900A (xx) |
BG (1) | BG105715A (xx) |
BR (1) | BR9916839A (xx) |
CA (1) | CA2352326A1 (xx) |
CZ (1) | CZ20012139A3 (xx) |
DE (1) | DE69928568T2 (xx) |
EA (1) | EA200100687A1 (xx) |
EE (1) | EE200100339A (xx) |
ES (1) | ES2253928T3 (xx) |
GE (1) | GEP20043172B (xx) |
HK (1) | HK1042057A1 (xx) |
HR (1) | HRP20010473A2 (xx) |
HU (1) | HUP0104844A3 (xx) |
ID (1) | ID30250A (xx) |
IL (1) | IL143939A0 (xx) |
IS (1) | IS5969A (xx) |
MA (1) | MA26768A1 (xx) |
NO (1) | NO20013099L (xx) |
NZ (1) | NZ512859A (xx) |
OA (1) | OA11733A (xx) |
PL (1) | PL348326A1 (xx) |
SK (1) | SK8712001A3 (xx) |
TR (1) | TR200101871T2 (xx) |
WO (1) | WO2000037141A1 (xx) |
YU (1) | YU45401A (xx) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010068738A1 (en) | 2008-12-10 | 2010-06-17 | Dana-Farber Cancer Institute, Inc. | Mek mutations conferring resistance to mek inhibitors |
WO2011106298A1 (en) | 2010-02-25 | 2011-09-01 | Dana-Farber Cancer Institute, Inc. | Braf mutations conferring resistance to braf inhibitors |
WO2013169858A1 (en) | 2012-05-08 | 2013-11-14 | The Broad Institute, Inc. | Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DZ3401A1 (fr) | 2000-07-19 | 2002-01-24 | Warner Lambert Co | Esters oxygenes d'acides 4-iodophenylamino benzhydroxamiques |
US20020054869A1 (en) | 2000-09-01 | 2002-05-09 | Han-Mo Koo | Inhibition of mitogen-activated protein kinase (MAPK) pathway: a selective therapeutic strategy against melanoma |
EP1377312A4 (en) * | 2001-03-22 | 2004-10-06 | Andel Inst Van | ANTHRAX LETAL FACTOR INHIBITS TUMOR GROWTH AND ANGIOGENESIS |
IL149462A0 (en) | 2001-05-09 | 2002-11-10 | Warner Lambert Co | Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor |
CZ20022216A3 (cs) * | 2001-07-02 | 2003-05-14 | Warner-Lambert Company | Kombinační chemoterapie |
EP1676837A4 (en) * | 2003-10-08 | 2008-09-10 | Teijin Pharma Ltd | METHOD FOR PRODUCING AN AMINOPYRROLIDINE DERIVATIVE AND AN INTERMEDIATE COMPOUND |
RU2352558C2 (ru) | 2003-10-21 | 2009-04-20 | Уорнер-Ламберт Компани Ллс | Полиморфная форма n-[(r)-2,3-дигидроксипропокси]-3,4-дифтор-2-(2-фтор-4 йодфениламино)бензамида |
EA013212B1 (ru) | 2004-10-20 | 2010-04-30 | Лаборатуар Сероно Са | 3-ариламинопиридиновые производные |
CN1807413B (zh) * | 2005-09-28 | 2010-05-05 | 中国医学科学院医药生物技术研究所 | 咔唑磺酰胺衍生物及其制备方法 |
CA3052368A1 (en) | 2005-10-07 | 2007-04-19 | Exelixis, Inc. | Azetidines as mek inhibitors |
EP1790342A1 (de) | 2005-11-11 | 2007-05-30 | Zentaris GmbH | Pyridopyrazin-Derivate und deren Verwendung als Modulatoren der Signaltransduktionswege |
CA2628039A1 (en) | 2005-11-11 | 2007-05-18 | Aeterna Zentaris Gmbh | Novel pyridopyrazines and their use as modulators of kinases |
US8217042B2 (en) | 2005-11-11 | 2012-07-10 | Zentaris Gmbh | Pyridopyrazines and their use as modulators of kinases |
CN105106199A (zh) | 2006-12-14 | 2015-12-02 | 埃克塞利希斯股份有限公司 | 使用mek抑制剂的方法 |
AU2011224410B2 (en) | 2010-03-09 | 2015-05-28 | Dana-Farber Cancer Institute, Inc. | Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy |
CN103301096B (zh) * | 2012-03-14 | 2015-05-06 | 中国中化股份有限公司 | 取代二苯胺类化合物作为制备抗肿瘤药物的应用 |
MY186549A (en) | 2012-10-12 | 2021-07-26 | Exelixis Inc | Novel process for making compounds for use in the treatment of cancer |
EP2963114B1 (en) | 2013-02-27 | 2018-12-12 | Daiichi Sankyo Company, Limited | Method for predicting responsiveness to compound inhibiting mapk signal transduction pathway |
CN105384754B (zh) * | 2014-09-02 | 2018-04-20 | 上海科州药物研发有限公司 | 作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途 |
CN111909053B (zh) * | 2020-08-06 | 2022-12-06 | 湖北省生物农药工程研究中心 | 基于二芳胺单元的酰胺类衍生物及其制备方法和应用 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL112248A0 (en) * | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
AU2092597A (en) * | 1996-03-07 | 1997-09-22 | Novartis Ag | Antiproliferative combinations, containing raf-targeted oligonucleotides and chemotherapeutic compounds |
WO1998037881A1 (en) * | 1997-02-28 | 1998-09-03 | Warner Lambert Company | Method of treating or preventing septic shock by administering a mek inhibitor |
WO1998042830A2 (en) * | 1997-03-21 | 1998-10-01 | Board Of Regents, The University Of Texas System | Noey2 gene compositions and methods of use |
US6002008A (en) * | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
US6040321A (en) * | 1997-11-12 | 2000-03-21 | Bristol-Myers Squibb Company | Aminothiazole inhibitors of cyclin dependent kinases |
US5959097A (en) * | 1998-11-20 | 1999-09-28 | Isis Pharmaceuticals, Inc. | Antisense modulation of MEK2 expression |
-
1999
- 1999-12-21 EE EEP200100339A patent/EE200100339A/xx unknown
- 1999-12-21 CA CA002352326A patent/CA2352326A1/en not_active Abandoned
- 1999-12-21 WO PCT/US1999/030485 patent/WO2000037141A1/en active IP Right Grant
- 1999-12-21 SK SK871-2001A patent/SK8712001A3/sk unknown
- 1999-12-21 JP JP2000589248A patent/JP2002532570A/ja active Pending
- 1999-12-21 ES ES99966523T patent/ES2253928T3/es not_active Expired - Lifetime
- 1999-12-21 AU AU22039/00A patent/AU2203900A/en not_active Abandoned
- 1999-12-21 EP EP99966523A patent/EP1140291B1/en not_active Expired - Lifetime
- 1999-12-21 AP APAP/P/2001/002175A patent/AP2001002175A0/en unknown
- 1999-12-21 CN CN99815040A patent/CN1333698A/zh active Pending
- 1999-12-21 CZ CZ20012139A patent/CZ20012139A3/cs unknown
- 1999-12-21 KR KR1020017007874A patent/KR20010099877A/ko not_active Application Discontinuation
- 1999-12-21 HU HU0104844A patent/HUP0104844A3/hu unknown
- 1999-12-21 ID IDW00200101616A patent/ID30250A/id unknown
- 1999-12-21 TR TR2001/01871T patent/TR200101871T2/xx unknown
- 1999-12-21 GE GEAP19996007A patent/GEP20043172B/en unknown
- 1999-12-21 IL IL14393999A patent/IL143939A0/xx unknown
- 1999-12-21 PL PL99348326A patent/PL348326A1/xx not_active Application Discontinuation
- 1999-12-21 YU YU45401A patent/YU45401A/sh unknown
- 1999-12-21 EA EA200100687A patent/EA200100687A1/ru unknown
- 1999-12-21 AT AT99966523T patent/ATE310567T1/de not_active IP Right Cessation
- 1999-12-21 BR BR9916839-1A patent/BR9916839A/pt not_active Application Discontinuation
- 1999-12-21 NZ NZ512859A patent/NZ512859A/en unknown
- 1999-12-21 OA OA1200100161A patent/OA11733A/en unknown
- 1999-12-21 DE DE69928568T patent/DE69928568T2/de not_active Expired - Fee Related
-
2001
- 2001-06-14 IS IS5969A patent/IS5969A/is unknown
- 2001-06-21 NO NO20013099A patent/NO20013099L/no not_active Application Discontinuation
- 2001-06-21 HR HR20010473A patent/HRP20010473A2/hr not_active Application Discontinuation
- 2001-07-18 BG BG105715A patent/BG105715A/xx unknown
- 2001-07-19 MA MA26275A patent/MA26768A1/fr unknown
-
2002
- 2002-05-04 HK HK02103397.1A patent/HK1042057A1/zh unknown
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010068738A1 (en) | 2008-12-10 | 2010-06-17 | Dana-Farber Cancer Institute, Inc. | Mek mutations conferring resistance to mek inhibitors |
WO2011106298A1 (en) | 2010-02-25 | 2011-09-01 | Dana-Farber Cancer Institute, Inc. | Braf mutations conferring resistance to braf inhibitors |
EP3028699A1 (en) | 2010-02-25 | 2016-06-08 | Dana-Farber Cancer Institute, Inc. | Braf mutations conferring resistance to braf inhibitors |
WO2013169858A1 (en) | 2012-05-08 | 2013-11-14 | The Broad Institute, Inc. | Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BG105715A (en) | Combination chemotherapy | |
BG105369A (en) | Arylpiperazines and their use as metalloproteinase inhibiting agent (mmp | |
AP2001002103A0 (en) | Substituted phenyl derivatives, their preparation and use. | |
DE69713402T2 (de) | Liganden des neuropeptids y | |
BG103413A (en) | Derivatives of sulphinic acid, their production and application | |
PT1070056E (pt) | Inibidores de pde iii/iv a base de ftalazinona | |
CY2509B1 (en) | New thiazole derivatives with phosphodiesterase-inhibitting effect | |
AU3110999A (en) | Disubstituted pyrazolines and triazolines as factor xa inhibitors | |
IL145639A0 (en) | C10 heterosubstituted acetate taxanes as antitumor agents | |
PL343374A1 (en) | Anti-inflammatory, antibacterial benzyl phenol agents | |
MX9708827A (es) | Derivados novedosos de amidina utiles como inhibidores de agregacion plaquetaria y como vasodilatadores. | |
PL341239A1 (en) | Dihydrobenzofuranes | |
WO2005046672A3 (fr) | Utilisation d’inhibiteurs de glucosidase pour une therapie de la mucoviscidose | |
IL153352A0 (en) | Coumarin derivatives with comt inhibiting activity | |
AP2001002045A0 (en) | FKBP inhibitors. | |
GB2324091A (en) | Metalloproteinase inhibitors | |
BG105964A (en) | C(10) carbonate substituted taxanes and their use as antitumor agents | |
MXPA05006957A (es) | Nuevos derivados de fosforamida. | |
WO2000035428A3 (de) | Tricyclische stickstoffheterocyclen als pde iv inhibitoren | |
BG105966A (en) | C7 carbonate substituted taxanes and their application as antitumor agents | |
BG105252A (en) | Isoquinolines as urokinase inhibitors | |
BG105965A (en) | C10 ester substituted taxanes and their application as antitumor agents | |
MX9602949A (es) | 2-oxa y tia-zolinas artropodicidas. | |
MY119841A (en) | Cephalosporines having cyclic aminoguanidine substituents as antibiotics. | |
RS20050181A (xx) | Novi benzonaftiridini |